Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

gammadelta T cells: a new frontier for immunotherapy?

Lawrence S Lamb1, Richard D Lopez

  • 1Department of Medicine, Division of Hematology and Oncology, Bone Marrow Transplantation Program, University of Alabama at Birmingham School of Medicine, 32594-0006, USA. lslamb@uabmc.edu

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|March 4, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sociodemographic factors and timing of allogeneic hematopoietic stem cell transplantation in myeloproliferative neoplasms.

Bone marrow transplantation·2026
Same author

Impact of donor age on cognitive recovery in allogenic hematopoietic stem cell transplant patients with mild cognitive impairment.

Bone marrow transplantation·2026
Same author

Exploring Perspectives on Feasibility, Challenges, and Support Needs for Chlorhexidine Gluconate (CHG) Bathing in the Outpatient Setting for Hematopoietic Cell Transplant Recipients: A Qualitative Study.

Transplantation and cellular therapy·2025
Same author

Food insecurity prior to hematopoietic stem cell transplant is associated with malnutrition and worse outcomes.

Bone marrow transplantation·2025
Same author

Exploring facilitators and barriers to daily chlorhexidine gluconate bathing in adult patients undergoing hematopoietic stem cell transplantation.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2024
Same author

Temozolomide and the PARP Inhibitor Niraparib Enhance Expression of Natural Killer Group 2D Ligand ULBP1 and Gamma-Delta T Cell Cytotoxicity in Glioblastoma.

Cancers·2024
Same journal

ASTCT Notes.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2021
Same journal

ASTCT Notes.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2021
Same journal

End of headings.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2021
Same journal

ASTCT Notes.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2021
Same journal

Improving Hematopoietic Stem Cell Transplant in the Elderly: Can We Finally Start to Impact Nonrelapse Mortality?

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2020
Same journal

Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2020
See all related articles

Gammadelta T cells show promise for cancer immunotherapy by augmenting innate immune responses against malignancies. Research is overcoming challenges to deliver these cells for treating blood and solid tumors.

Area of Science:

  • Immunology
  • Oncology
  • Cell Therapy

Background:

  • Cytolytic effector cells have been researched for cancer therapy for two decades.
  • Previous research focused on natural killer cells and CD8+ T cells, with limited attention to gammadelta T cells.
  • Understanding gammadelta T cell tumor responses and obtaining sufficient cells for clinical use have been challenges.

Purpose of the Study:

  • To discuss the biological and clinical rationale for gammadelta T cell-based immunotherapies.
  • To explore the potential of gammadelta T cells in treating various malignant conditions.
  • To address practical limitations hindering the clinical application of gammadelta T cells.

Main Methods:

  • Review of existing literature on gammadelta T cell cytotoxicity and tumor immunology.

Related Experiment Videos

  • Discussion of strategies to overcome challenges in gammadelta T cell isolation and expansion.
  • Exploration of autologous and allogeneic approaches for gammadelta T cell therapy.

    • Main Results:

    • Gammadelta T cells can mediate antitumor cytotoxicity and augment innate immune responses.
    • Infusing supraphysiological numbers of tumor-reactive gammadelta T cells may restore antitumor immunity.
    • Progress is being made in overcoming practical limitations for clinical delivery.

    Conclusions:

    • Gammadelta T cells represent a promising therapeutic strategy for cancer immunotherapy.
    • Further research and technological advancements are needed to fully realize the potential of gammadelta T cell therapy.
    • Gammadelta T cell therapy holds potential for treating both hematologic and solid tumors.